{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T05:24:34Z","timestamp":1786944274556,"version":"build-2736575974"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The treatment of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome has largely focused on immunosuppression with little impact on the atopic manifestations of the disease. Dupilumab therapy has been used successfully in primary atopic diseases and immune regulatory disorders to control type 2 inflammation. Indeed, it has been reported in two prior IPEX cases, but in combination with immunosuppressive agents. Here, we are the first to report the clinical and immunologic impact of dupilumab monotherapy in IPEX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case<\/jats:title>\n                    <jats:p>A 4-year-old boy with a confirmed hemizygous Forkhead box protein 3 (FOXP3) missense variant (c.1150G&amp;gt;A; p.Ala384Thr) presented with severe, treatment-refractory atopic dermatitis beginning in the newborn period, failure to thrive, lymphadenopathy, food and environmental allergies, asthma, recurrent febrile neutropenia, and type 1 diabetes mellitus, with a peak IgE of 74,625 IU\/mL. Following initiation of dupilumab monotherapy at age 2, the patient had a marked improvement in atopic dermatitis by Eczema Area and Severity Index (EASI) score, a rapid decline in serum IgE, improved growth, reduced respiratory hospitalizations, and a profoundly improved quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Immunologically, dupilumab effectively suppressed IgE and plasma interleukin-4 (IL-4) and IL-13 to healthy control levels. In addition, C-C motif chemokine ligand 27 (CCL27), important for cutaneous T-cell trafficking, was detected at healthy control levels. Upstream alarmins, eosinophil mediators, T helper 1 (Th1) cytokines, and Treg-specific demethylated region (TSDR) demethylation remained elevated\u2014indicating ongoing systemic immune dysregulation not fully addressed by dupilumab alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates that dupilumab monotherapy can effectively suppress the IL-4\/IL-13 axis and substantially improve atopic manifestations in IPEX, potentially by restoring skin-specific immune tolerance through rebalancing cutaneous T-cell trafficking. These findings support dupilumab as a targeted adjunctive therapy for the atopic features of IPEX and provide a rationale for the systematic study of dupilumab alone or in combination with other immunosuppression regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1923415","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:34:07Z","timestamp":1786941247000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Effective IL-4\/IL-13 axis suppression and resolution of severe atopic dermatitis by dupilumab monotherapy in a patient with IPEX syndrome"],"prefix":"10.3389","volume":"17","author":[{"given":"Mohammed","family":"Alshanti","sequence":"first","affiliation":[{"name":"Division of Allergy and Immunology, Department of Pediatrics, Sheikh Khalifa Medical City","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"MacDougall","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, Rheumatology, Stanford University","place":["Stanford, CA, United States"]},{"name":"Division of Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford University","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve Nida","family":"Gokbak","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, Rheumatology, Stanford University","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshaya","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, Rheumatology, Stanford University","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna Aref","family":"Alzaabi","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Sheikh Khalifa Medical City","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie L.","family":"Alexander","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, Rheumatology, Stanford University","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Bacchetta","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, Rheumatology, Stanford University","place":["Stanford, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba Mohammed","family":"Shendi","sequence":"additional","affiliation":[{"name":"Division of Allergy and Immunology, Department of Pediatrics, Sheikh Khalifa Medical City","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2023.11.021","article-title":"Ipex syndrome from diagnosis to cure, learning along the way","volume":"153","author":"Bacchetta","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jaci.2017.10.041","article-title":"Longterm follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study","volume":"141","author":"Barzaghi","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jaci.2022.09.013","article-title":"Epigenetic and immunological indicators of IPEX disease in subjects with FOXP3 gene mutation","volume":"151","author":"Narula","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg6822","article-title":"Identification of unstable regulatory and autoreactive effector T cells that are expanded in patients with FOXP3 mutations","volume":"15","author":"Borna","year":"2023","journal-title":"Sci Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.995304","article-title":"Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis","volume":"13","author":"Caruso","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s10875-025-01979-8","article-title":"Pediatric IPEX-associated dermatitis responds to dupilumab: Evidence from skin transcriptomics and immune profiling","volume":"46","author":"Yang","year":"2026","journal-title":"J ClinImmunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41419-024-06679-6","article-title":"Study of the potential role of CASPASE-10 mutations in the development of autoimmune lymphoproliferative syndrome","volume":"15","author":"Consonni","year":"2024","journal-title":"Cell Death Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/cea.70082","article-title":"Complementary analysis of local and systemic effects of dupilumab in paediatric AD using tape strips and serum","volume":"55","author":"van der Rijst","year":"2025","journal-title":"Clin Exp Allergy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.jid.2021.01.022","article-title":"Early and long-term effects of dupilumab treatment on circulating T-cell functions in patients with moderate-to-severe atopic dermatitis","volume":"141","author":"Bakker","year":"2021","journal-title":"J Invest Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1923415\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T04:34:07Z","timestamp":1786941247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1923415\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":10,"alternative-id":["10.3389\/fimmu.2026.1923415"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1923415","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1923415"}}